However if Celgene is able to gain approval for use in psoriasis as well, this will boost its revenues. The drug was filed in Europe in January this year, with a European approval launch ...

Celgene's drug is not the first oral treatment in the field – Pfizer's Xeljanz (tofacitinib) was approved for the treatment of rheumatoid arthritis in 2012, but has struggled to gain market share.

Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...

Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, ...

Celgene's apremilast ... 68% of the $3.5 billion global psoriasis market is captured by biologic therapies; topical agents and conventional systemic drugs account for ∼25% and ∼7%, respectively.

Celgene has acquired Gloucester Pharmaceuticals ... Merck) (see Nature Rev. Drug Discov. 6, 21–22; 2007) by the FDA in October 2006. Romidepsin and vorinostat have very different chemical ...